Fig. 2.

ASTEX represses SARS-CoV-2-mediated activation of the mTOR pathway. (A) Heatmap of transcriptomic analysis of uninfected Calu-3 cells (Mock) or those pre-treated with vehicle (Veh), ASTEX, or remdesivir (Rem) followed by SARS-CoV-2 (CoV-2) exposure (B). Sequencing data demonstrating that ASTEX repress the mTOR pathway activators in infected cells down to levels comparable to uninfected cells (C). Phospho-array (n = 6 replicates) of cell lysates showing post-translational repression of the mTOR in ASTEX-pretreated cells. ASTEX represses mTOR (through hypophosphorylation of Thr2446; D), AKT1 (through hyperphosphorylation of Thr72; (D), and P70S6K (through hypophosphorylation of Thr421 and Ser423; E, F) in ASTEX-pretreated infected cells compared to vehicle. Analysis done using Student's T-test; *p < 0.05, **p < 0.01, ***p < 0.001 using a 95% CI.